(Q43016395)

12 November 2017

Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan (English)

1 reference

12 November 2017

0 references

1 reference

Takehiko Wago

1

1 reference

12 November 2017

Takanobu Yoshimoto

2

1 reference

12 November 2017

Itaru Akaza

3

1 reference

12 November 2017

Kyoichiro Tsuchiya

4

1 reference

12 November 2017

Hajime Izumiyama

5

1 reference

12 November 2017

Masaru Doi

6

1 reference

12 November 2017

Yukio Hirata

7

1 reference

12 November 2017

17 June 2010

1 reference

12 November 2017

Hypertension Research

1 reference

12 November 2017

33

1 reference

12 November 2017

8

1 reference

12 November 2017

796-801

1 reference

https://scigraph.springernature.com/pub.10.1038/hr.2010.107

12 November 2017

0 references

cites work

Advanced endothelial dysfunction in diabetic patients with multiple risk factors; importance of insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

Endothelial function and dysfunction: testing and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Possible beneficial effect of telmisartan on glycemic control in diabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Effects of telmisartan on fat distribution in individuals with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Jananese Society of Hypertension (JSH) Guidelines for Self-Monitoring of Blood Pressure at Home

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Telmisartan improves endothelial function in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Telmisartan Shows an Equivalent Effect of Vitamin C in Further Improving Endothelial Dysfunction After Glycemia Normalization in Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Hypoadiponectinemia: a common basis for diseases associated with overnutrition

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Adiponectin stimulates production of nitric oxide in vascular endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Antihypertensive therapy and endothelial function

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance

1 reference

https://api.crossref.org/works/10.1038%2FHR.2010.107

7 January 2021

Identifiers

DOI

10.1038/HR.2010.107

1 reference

12 November 2017

1 reference